Assessing cervical lymph nodes response in head and neck cancer after treatment
Official title: The Value of Contrast-enhanced Ultrasound in Assessing the Response of Cervical Lymph Nodes After Neoadjuvant Chemoimmunotherapy for Head and Neck Squamous Cell Carcinoma
Run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT06727162 · Data updated 2026-11-12
This study is testing if a special ultrasound can help doctors see how well treatment is working on lymph nodes in patients with head and neck cancer.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Guangzhou, Guangdong) |
| Status | Recruiting |
| Started | August 13, 2024 |
| Main results expected | October 10, 2025 |
| Study ends | October 10, 2025 |
| Registry record updated | December 10, 2024 |
| Trial ID | NCT06727162 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with histopathologically confirmed head and neck squamous cell carcinoma who have received neoadjuvant chemoimmunotherapy and are scheduled for radical surgery with lymph node dissection.
✕Probably not a fit
Patients who have not completed a full course of neoadjuvant therapy or have a history of prior treatment for head and neck cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study evaluates the effectiveness of contrast-enhanced ultrasound (CEUS) in assessing the response of cervical lymph nodes in patients with head and neck squamous cell carcinoma (HNSCC) who have undergone neoadjuvant chemoimmunotherapy. The study aims to determine how well CEUS can identify changes in lymph node status after treatment, which is crucial for guiding subsequent surgical decisions. By focusing on the lymph nodes, the research seeks to improve treatment planning and potentially reduce unnecessary surgeries. The study is conducted at Sun Yat-Sen Memorial Hospital in Guangzhou, Guangdong.
Why it matters
Potential benefit: If successful, this study could lead to more accurate assessments of lymph node response, improving treatment decisions and outcomes for patients with head and neck cancer.
How similar studies have gone: While there is ongoing research into the use of imaging techniques for assessing cancer treatment responses, the specific application of CEUS for cervical lymph nodes in this context is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * (1) Histopathologically confirmed head and neck squamous cell carcinoma; (2) Received neoadjuvant chemoimmunotherapy; (3) Diagnosed with cN+ by CT/MRI before treatment; (4) Underwent radical surgical treatment plus cervical lymph node dissection at this center. Exclusion Criteria: * (1) Did not receive a full course of neoadjuvant therapy; (2) History of treatment for head and neck; (3) Clinical evidence of distant metastasis found during preoperative examination.
Where it's running
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China Recruiting
Study contacts
- Study coordinator: Lin Peiliang, Doctor
- Phone: 86-020-34071539
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Neoadjuvant therapy with nimotuzumab, toripalimab, nab-paclitaxel, and cisplatin for locally advanced head and neck cancer
This study tests a pre-surgery treatment combining targeted therapy, immunotherapy, and chemotherapy to see if it helps patients with locally advanced, resectable head and neck squamous cell carcinoma.
-
ICG with near-infrared imaging to visualize head and neck cancer during surgery
This study tests whether first-window indocyanine green fluorescence seen during surgery matches the cancer extent seen on pathology in patients with head and neck squamous cell carcinoma.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
-
Online Sharing for Head & Neck Cancer Support
A mobile app designed for adults with head and neck cancer undergoing radiotherapy to see if daily social sharing and peer interaction can help reduce psychological distress.
-
Telisotuzumab Adizutecan with Pembrolizumab as first-line treatment for recurrent or metastatic head and neck cancer
This study tests a combination treatment to see if it helps people with newly diagnosed recurrent or metastatic head and neck squamous cell carcinoma who express the c-Met protein.
-
Mild heat therapy added to standard treatment for locally advanced head and neck cancer
This early-stage trial tests whether mild hyperthermia can be safely added to standard radiotherapy with or without chemotherapy for locally advanced head and neck cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.